Copyright investors
Exact Sciences (EXAS) had its Relative Strength (RS) Rating upgraded from 80 to 83 Tuesday. This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database. Over 100 years of market history shows that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves. Exact Sciences is building a cup without handle with a 72.83 buy point. See if the stock can break out in volume at least 40% higher than normal. Earnings grew 243% last quarter, up from 57% in the prior report. Revenue also increased, from 16% to 20%. The company holds the No. 14 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals (AUPH), Halozyme Therapeutics (HALO) and Incyte (INCY) are among the top 5 highly rated stocks within the group. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
